Download PDF
Thromb Haemost 2003; 90(03): 414-421
DOI: 10.1160/TH02-09-0104
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs

Chengliang Wu
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
2   Jiangsu Institute of Hematology, Suzhou University, Suzhou, P.R. China
,
Ningzheng Dong
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
2   Jiangsu Institute of Hematology, Suzhou University, Suzhou, P.R. China
,
Valdeci da Cunha
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
Baby Martin-McNulty
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
Katherine Tran
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
Mariko Nagashima
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
Qingyu Wu
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
John Morser
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
,
Yi-Xin Wang
1   Departments of Cardiovascular Research and Pharmacology, Berlex Biosciences, Richmond, California, USA
› Author Affiliations
Further Information

Publication History

Received 20 September 2002

Accepted after resubmission 22 May 2003

Publication Date:
05 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Studies have shown that inhibition of TAFI by small peptides enhances pharmacological effects of tPA in animal models of thrombosis, suggesting that TAFI modulates the fibrinolytic system. In this study, we investigated the effect of activated human TAFI (TAFIa) on endogenous fibrinolysis in a rat model of intravascular fibrin deposition. 125I-labeled fibrinogen was injected intravenously followed by a bolus injection of batroxo-bin, a thrombin-like enzyme. Batroxobin cleaved fibrinogen to form insoluble fibrin that was deposited in tissues, including the lungs. This was shown by a decrease of radioactivity in the blood as a result of consumption of 125I-labeled fibrinogen and an elevation of radioactivity in the lungs 5 min following batroxobin administration. Endogenous fibrinolysis was detected by a gradual increase in radioactivity in the blood and a decrease in radioactivity in the lungs at 30 min, an indication of radio-labeled fibrin degradation products (FDPs) being released into the circulation from the tissues. Intravenous administration of human TAFIa dose-dependently attenuated the later phase reduction of radioactivity in the lungs. When the dose of TAFIa was 218 μg/kg, giving a peak plasma level of TAFIa 0.9 ± 0.05 μg/ml, the spontaneous fibrinolysis was completely prevented. These results provide direct evidence that an increase in circulating TAFIa impairs endogenous clot lysis in a rat model of fibrin deposition.

Keywords

TAFI - PAI-1 - batroxobin - fibrinolysis - rat - lung fibrin deposition
 

  • References

  • 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
    PubMedSearch in Google Scholar
  • 2 Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
    CrossrefPubMedSearch in Google Scholar
  • 3 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
    CrossrefPubMedSearch in Google Scholar
  • 5 Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
    CrossrefPubMedSearch in Google Scholar
  • 6 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
    CrossrefPubMedSearch in Google Scholar
  • 7 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
    CrossrefPubMedSearch in Google Scholar
  • 8 Lin JH, McLean K, Morser J. et al. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem 1994; 269: 25021-30.
    PubMedSearch in Google Scholar
  • 9 Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation. J Biol Chem 2000; 275: 22942-47.
    CrossrefPubMedSearch in Google Scholar
  • 10 Lenfors S, Gustafsson D. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors. Semin Thromb Hemost 1996; 22: 335-42.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Abrahamsson T, Nerme V, Stromqvist M. et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-26.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Bell Jr WR. Defibrinogenating enzymes. Drugs 1997; 54: 18-30. discussion 30-1
    CrossrefPubMedSearch in Google Scholar
  • 13 Pirkle H, Stocker K. Thrombin-like enzymes from snake venoms: an inventory. For the Subcommittee on Nomenclature of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 65: 444-50.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Pizzo SV, Schwartz ML, Hill RL, McKee PA. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. J Clin Invest 1972; 51: 2841-50.
    CrossrefPubMedSearch in Google Scholar
  • 15 Regoeczi E, Gergely J, McFarlane AS. In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I. J Clin Invest 1966; 45: 1202-12.
    CrossrefPubMedSearch in Google Scholar
  • 16 Klocking HP, Markwardt F, Guttner J. On the mechanism of batroxobin-induced fibrinolysis. Pharmazie 1989; 44: 504-5.
    PubMedSearch in Google Scholar
  • 17 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedSearch in Google Scholar
  • 18 Minnema MC, Friederich PW, Levi M. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
    CrossrefPubMedSearch in Google Scholar
  • 19 Gresele P, Momi S, Berrettini M. et al. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest 1998; 101: 667-76.
    CrossrefPubMedSearch in Google Scholar
  • 20 Nagashima M, Yin ZF, Zhao L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
    CrossrefPubMedSearch in Google Scholar
  • 21 Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
    CrossrefPubMedSearch in Google Scholar
  • 22 Stromqvist M, Schatteman K, Leurs J. et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 12-7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
    PubMedSearch in Google Scholar
  • 24 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
    PubMedSearch in Google Scholar
  • 25 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
    PubMedSearch in Google Scholar
  • 26 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803.
    PubMedSearch in Google Scholar
  • 27 Carmeliet P, Stassen JM, Schoonjans L, Ream B. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
    CrossrefPubMedSearch in Google Scholar
  • 28 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
    CrossrefPubMedSearch in Google Scholar
  • 29 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
    CrossrefPubMedSearch in Google Scholar
  • 30 Padro T, Quax PH, van den Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin. Arterioscler Thromb 1994; 14: 1459-65.
    CrossrefPubMedSearch in Google Scholar
  • 31 Levi M, ten Cate H, Bauer KA. et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
    CrossrefPubMedSearch in Google Scholar
  • 32 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985; 290: 1453-6.
    CrossrefPubMedSearch in Google Scholar
  • 33 Aillaud MF, Juhan-Vague I, Alessi MC. et al. Increased PA-inhibitor levels in the postoperative period—no cause-effect relation with increased cortisol. Thromb Haemost 1985; 54: 466-8.
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J (Clin Res Ed) 1985; 291: 573-4.
    CrossrefPubMedSearch in Google Scholar
  • 35 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
    CrossrefPubMedSearch in Google Scholar
  • 36 Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-7.
    CrossrefPubMedSearch in Google Scholar